Marinus: FDA Accepts Application for Ganaxolone in CDKL5 Deficiency Disorder
September 20 2021 - 8:16AM
Dow Jones News
By Michael Dabaie
Marinus Pharmaceuticals Inc. said the U.S. Food and Drug
Administration accepted for filing its new drug application for
ganaxolone in the treatment of seizures associated with CDKL5
deficiency disorder, a rare, genetic epilepsy.
The FDA granted the application priority review designation and
assigned a prescription drug user fee act action date of March 20,
2022.
In its acceptance letter, the FDA indicated it isn't currently
planning to hold an advisory committee meeting to discuss the
application.
The acceptance of the NDA for filing enables the company to draw
$30 million of additional cash under its May 11, 2021, credit
financing agreement with Oaktree Capital Management L.P.
If the NDA is approved by Dec. 31, 2022, the company can draw an
additional $30 million under the agreement.
The FDA gives priority review designation to an investigational
medicine that would be a significant improvement in the safety or
effectiveness of the treatment of a serious condition. The
designation accelerates the timing of the FDA review of the
application compared to a standard review.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 20, 2021 08:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Apr 2023 to Apr 2024